CALGARY, June 19, 2014 /PRNewswire/ – Oncolytics Biotech Inc. (TSX: ONC,
NASDAQ: ONCY) announced today that all nominees listed in the
management information circular dated May 9, 2014 were elected as
directors at its 2014 Annual Meeting of Shareholders, held on Wednesday
June 18th, 2014. On a vote by ballot, the following 10 nominees proposed by
management were elected as Directors of Oncolytics to serve until the
Company`s next Annual Meeting of Shareholders or until their successors
are elected or appointed, with shares represented at the meeting voting
in favour of individual nominees as follows:
| Director | For | % | Withheld | % |
| Ger van Amersfoort | 13,138,482 | 93.53% | 909,206 | 6.47% |
| Matthew Coffey | 12,772,377 | 90.92% | 1,275,312 | 9.08% |
| Jim Dinning | 11,675,341 | 83.11% | 2,372,347 | 16.89% |
| Linda Hohol | 12,509,026 | 89.05% | 1,538,662 | 10.95% |
| Angela Holtham | 12,520,502 | 89.13% | 1,527,186 | 10.87% |
| Ed Levy | 12,369,473 | 88.05% | 1,678,215 | 11.95% |
| Mark Lievonen | 11,778,509 | 83.85% | 2,269,179 | 16.15% |
| Wayne Pisano | 13,090,751 | 93.19% | 956,937 | 6.81% |
| Robert Schultz | 12,849,006 | 91.47% | 1,198,682 | 8.53% |
| Brad Thompson | 12,299,004 | 87.55% | 1,748,684 | 12.45% |
About Oncolytics Biotech Inc.
Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics’ clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN®, its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended. Forward-looking statements, including the Company’s belief as
to the potential of REOLYSIN as a cancer therapeutic; the Company’s
expectations as to the success of its research and development programs
in 2014 and beyond, the Company’s planned operations, the value of the
additional patents and intellectual property; the Company’s
expectations related to the applications of the patented technology;
the Company’s expectations as to adequacy of its existing capital
resources; the design, timing, success of planned clinical trial
programs; and other statements related to anticipated developments in
the Company’s business and technologies involve known and unknown risks
and uncertainties, which could cause the Company’s actual results to
differ materially from those in the forward-looking statements. Such
risks and uncertainties include, among others, the availability of
funds and resources to pursue research and development projects, the
efficacy of REOLYSIN as a cancer treatment, the success and timely
completion of clinical studies and trials, the Company’s ability to
successfully commercialize REOLYSIN, uncertainties related to the
research and development of pharmaceuticals, uncertainties related to
the regulatory process and general changes to the economic environment.
Investors should consult the Company’s quarterly and annual filings
with the Canadian and U.S. securities commissions for additional
information on risks and uncertainties relating to the forward-looking
statements. Investors are cautioned against placing undue reliance on
forward-looking statements. The Company does not undertake to update
these forward-looking statements, except as required by applicable
laws.
SOURCE Oncolytics Biotech Inc.
Released June 19, 2014